Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

203

2:27 Soluble Mediators of Post-COVID-19 Fibrotic Lung Remodeling: A Proteomic Approach/ S. Holton, Seattle, WA 2:39 A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities/ M. Moll, Boston, MA 2:51 Activated T Regulatory Responses in Interstitial Lung Disease/ T.E. Velez, Charlottesville, VA 3:03 Circulating T Cells in Sarcoidosis Have an Activated Phenotype That Correlates With Disease Outcome/ J.R. Miedema, Rotterdam, Netherlands 3:15 Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells/ D. Siefker, San Diego, CA 3:27 TRPV4 Is a Key Mechanosensor in Macrophages That Drives Myofibroblast Differentiation Through the TGF-ß Pathway/ R.G. Scheraga, Cleveland, OH 3:39 Preclinical Granzyme B PET Imaging for Pulmonary Fibrosis Detection and Treatment Response Evaluation/ Y. Zhang, Birmingham, AL 3:51 Functional Imaging Signatures of Chronic Hypersensitivity Pneumonitis Utilizing Hyperpolarized 129 Xe MRI and Spectroscopy/ M. Kocher, Durham, NC 4:03 Organic and Inorganic Exposures Are Associated With Radiologic Features in Patients With Fibrotic Interstitial Lung Disease/ S.D. Lok, Saskatoon, Canada

2:39 Respiratory Exacerbations and Lung Function Decline in People With Normal Spirometry and Smoking Exposure/ S. Fortis, Iowa City, IA 2:51 Loss of Airway Bacterial Phylogenetic Diversity in Mild to Moderate COPD Associates With Clinical and Pathobiological Markers of Disease Development/ Y.J. Huang, Ann Arbor, MI 3:03 Haemophilus -Driven Microbial Networks in COPD Associates with Airflow Decline, Frequent Exacerbations and Altered Mucus/ O.W. Meldrum, Singapore, Singapore 3:15 What a Lung Cancer Screening Cohort Can Tell Us About COPD: The University of Michigan Experience/ V.M. Scicluna, Ann Arbor, MI 3:27 Serum Kynurenine/Tryptophan Ratio Is a Marker of Lung Disease Severity in Current and Former Tobacco Cigarette Users With and Without COPD/ W.W. Labaki, Ann Arbor, MI 3:39 COPD With PH Secondary to Left Heart Disease Is Associated With Worse Survival/ R.C. Flowers, New York, NY 3:51 Disentangling Predictors of Overall and COPD-specific Mortality With Probabilistic Graphical Models/ T.C. Lovelace, Pittsburgh, PA 4:03 Impaired Exacerbation Recovery Is Associated With Reduced Resolvin D1 in Chronic Obstructive Pulmonary Disease/ L. Finney, London, United Kingdom

CLINICAL MINI SYMPOSIUM

CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

B95

TOWARDS IMPROVING ICU AND POST-ICU OUTCOMES

B94

DISEASE PROGRESSION AND MORBIDITY ALONG THE SPECTRUM OF COPD: FROM EARLY TO ESTABLISHED

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 202 B (Level 2)

2:15 p.m. - 4:15 p.m.

Marriott Marquis Downtown Liberty Ballroom, Salons I-L (Level M4)

Chairing: L.E. Ferrante, MD, MHS, ATSF, New Haven, CT C.T. Hough, MD, MSc, ATSF, Portland, OR T.J. Iwashyna, MD, PhD, Baltimore, MD Oral Presentations: 2:15 Clinician Familiarity Among Shift-level Interprofessional

Chairing: M.K. Han, MD, MS, ATSF, Ann Arbor, MI R. Kalhan, MD, MS, Chicago, IL D. Lafon, MD, Birmingham, AL Oral Presentations: 2:15 The Fev 1 as a Predictor of Future Health in Young Non-Obstructed Smokers/ Y. Tesfaigzi, Boston, MA 2:27 Airway Epithelial Gene Expression Associated With Domains of Resilience in Smokers Without Airflow Obstruction/ A. Oh, San Francisco, CA

ICU Teams Is Associated With Lower Mortality: A Network Analysis of Linked Clinician-patient Data/ D.K. Costa, Orange, CT

2:27 Associations Between Patient and Surrogate

Assessments of Pre-critical Illness Physical Function/ J. Gordon, Columbus, OH

ATS 2023 • Washington, DC